Tapentadol: uses, dosing, side effects & brands

Tapentadol is an opioid agonist sold in the U.S. under 3 brand and generic names, for pain. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Drug class: Opioid Agonist
Treats (across its forms): Pain
Available as: Tablet · Tablet, extended release
Sold as: 3 products — Nucynta, Nucynta ER and Tapentadol Hydrochloride
Prescription?: Prescription only
Generic available?: Yes
Half-life: about 5 hours (terminal half-life, on average, after oral administration)
What the pharmacy pays: about $336 for a 30-count supply — not your price
Boxed warning: Boxed warning

How Nucynta ER is dosed

From the FDA label for Nucynta ER (application NDA200533). Other tapentadol products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Tapentadol extended-release tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks. ( 2.1 ) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of tapentadol extended-release tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks ( 2.5 ). Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment, and response, and risk factors for addiction, abuse, and misuse. ( 5.1 ) Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with tapentadol extended-release tablets. Consider this risk when selecting an initial dose and when making dose adjustments. ( 2.1 , 5.2 ) Discuss availability of naloxone with the patient and caregiver and assess each patient's need for access to naloxone, both when initiating and renewing treatment with tapentadol extended-release tablets. Consider prescribing naloxone based on the patient's risk factors for overdose. ( 2.2 , 5.1 , 5.2 , 5.3 ) Instruct…

Everything below is the FDA label for Nucynta ER (tablet, extended release). Tapentadol is also sold as tablet, and those are different medicines to take — follow the label for the one you were prescribed.

Nucynta ER side effects

The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1) ] Life-Threatening Respiratory Depression [see Warnings and Precautions (5.2) ] Interaction with Benzodiazepine or Other CNS Depressants [see Warnings and Precautions (5.3) ] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.4) ] Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions (5.6) ] Serotonin Syndrome [see Warnings and Precautions (5.7) ] Adrenal Insufficiency [see Warnings and Precautions (5.9) ] Severe Hypotension [see Warnings and Precautions (5.10) ] Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.12) ] Seizures [see Warnings and Precautions (5.13) ] Withdrawal [see Warnings and Precautions (5.14) ] The most common (≥10%) adverse reactions were nausea, constipation, dizziness, headache, and somnolence. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical…

Who shouldn’t take Nucynta ER

Tapentadol extended-release tablets are contraindicated in patients with: Significant respiratory depression Acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment Known or suspected gastrointestinal obstruction, including paralytic ileus Hypersensitivity (e.g., anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product [see Adverse Reactions (6.2) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Drug Interactions (7) ] Significant respiratory depression ( 4 ) Acute or severe bronchial asthma ( 4 ) Known or suspected paralytic ileus ( 4 ) Hypersensitivity to tapentadol or to any other ingredients of the product ( 4 ) Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days. ( 4 )

Nucynta ER drug interactions

Table 3 includes clinically significant drug interactions with tapentadol extended-release tablets. Table 3. Clinically Significant Drug Interactions with tapentadol extended-release tablets Alcohol Clinical Impact: Concomitant use of alcohol with tapentadol extended-release tablets can result in an increase of tapentadol plasma levels and potentially fatal overdose of tapentadol. Intervention: Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol while on tapentadol extended-release tablet therapy [see Warnings and Precautions (5.3) ] . Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death [see Warnings and Precautions (5.3) ] . Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.1 , 5.2 , 5.3) ]. Examples: Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings and Precautions (5.7) ]. Intervention: If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue tapentadol extended-release tablet if serotonin syndrome is suspected. Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. Intervention: Do not use tapentadol extended-release tablet in patients taking MAOIs or within 14 days of stopping such treatment. Examples: phenelzine, tranylcypromine, linezolid Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of tapentadol extended-release tablets and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants Clinical Impact: Tapentadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Intervention: Because respiratory depression may be greater than otherwise expected, decrease the dosage of tapentadol extended-release tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Intervention: Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Intervention: Evaluate patients for signs of urinary retention or reduced gastric motility when tapentadol extended-release tablets are used concomitantly with anticholinergic drugs. Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics : Avoid use with tapentadol extended-release tablets because they may reduce analgesic effect of tapentadol extended-release tablets or precipitate withdrawal symptoms. ( 5.13 , 7 )

Every tapentadol product we track (3)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Tapentadol products
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Nucynta	Not yet rated	Prescription	Tablet	Generic	$336	View →
2	Nucynta ER Boxed warning	Not yet rated	Prescription	Tablet	Generic	$336	View →
3	Tapentadol Hydrochloride Boxed warning	Not yet rated	Prescription	Tablet	Generic	$336	View →

What tapentadol pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Tapentadol pill imprints
Imprint	Strength	Colour	Shape	Maker
O;M;50	50 mg	yellow	round	—
O;M;75	75 mg	yellow	round	—
O;M;100	100 mg	orange	round	—
OMJ;50	50 mg	white	oval	—
OMJ;100	100 mg	blue	oval	—
OMJ;150	150 mg	blue	oval	—
OMJ;200	200 mg	blue	oval	—
OMJ;250	250 mg	blue	oval	—
50	50 mg	yellow	round	—
75	75 mg	pink	round	—
100	100 mg	orange	round	—
O;M;50	50 mg	yellow	round	—

How long tapentadol keeps

No tapentadol label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.

Does tapentadol expire? The in-use limits and storage rules from its labels

Tapentadol and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

Maternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression. Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. Little information is available on the use of tapentadol during breastfeeding. Because it has opioid agonist activity, an alternate drug is preferred, especially when nursing a newborn or preterm infant. Monitor infants for excess sedation and respiratory depression. If tapentadol is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral tapentadol to 2 to 3 days at a low dose with close infant monitoring. If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.

Full LactMed record for tapentadol: levels in milk, effects in breastfed infants, and the drugs it would consider instead

National Institute of Child Health and Human Development, record revised December 15, 2025. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about tapentadol

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,139 reports naming tapentadol, and the FDA flagged 96% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

nausea109 reports
delirium72 reports
somnolence64 reports
dizziness63 reports
dyspnoea63 reports
constipation57 reports
malignant neoplasm progression57 reports
confusional state55 reports

Read these as a signal, not a rate. A report does not mean tapentadol caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved August 26, 2026.

How long tapentadol stays in your system

The elimination half-life of tapentadol is about 5 hours (terminal half-life, on average, after oral administration). This is the terminal (elimination) half-life, not a distribution phase. Tapentadol has NO active metabolite that outlasts the parent: the label states it is metabolized to N-desmethyl tapentadol and hydroxy tapentadol (plus glucuronide/sulfate conjugates), but "None of the metabolites contribute to the analgesic activity." Populations named by the label: geriatric — exposure (AUC) similar to young adults (16% lower Cmax), no half-life change noted. Hepatic impairment — half-life (t1/2) increases modestly, about 1.2-fold in mild and 1.4-fold in moderate impairment, with overall exposure much higher (AUC ~1.7-fold mild, ~4.2-fold moderate); severe hepatic impairment was not studied. Renal impairment — parent tapentadol AUC/Cmax were comparable across normal-to-severe renal function, but the inactive tapentadol-O-glucuronide accumulates markedly (up to ~5.5-fold in severe impairment). Half-life figures are from the extended-release label. Not a drug-test detection window and not dosing guidance.

Tapentadol extended-release tablets — DailyMed FDA label, §12.3 Pharmacokinetics ↗

Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.

Related calculators

Opioid MME calculator (morphine-equivalent dose) →How long it stays in your system →

Frequently asked questions

What is Nucynta ER?

Tapentadol extended-release tablet is an opioid agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, corresponding to 50, 100, 150, 200, and 250 mg of tapentadol free-base, respectively.

What kind of drug is tapentadol?

The FDA classifies tapentadol as an opioid agonist. Opioid agonists bind opioid receptors (mainly mu receptors) on nerves in the brain and spinal cord, dampening the release of pain-signaling chemicals so fewer pain messages reach the brain, which relieves moderate to severe pain. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

How long does tapentadol stay in your system?

The elimination half-life of tapentadol is about 5 hours (terminal half-life, on average, after oral administration) — that is how long the body takes to clear half of a dose. This is the terminal (elimination) half-life, not a distribution phase. Tapentadol has NO active metabolite that outlasts the parent: the label states it is metabolized to N-desmethyl tapentadol and hydroxy tapentadol (plus glucuronide/sulfate conjugates), but "None of the metabolites contribute to the analgesic activity." Populations named by the label: geriatric — exposure (AUC) similar to young adults (16% lower Cmax), no half-life change noted. Hepatic impairment — half-life (t1/2) increases modestly, about 1.2-fold in mild and 1.4-fold in moderate impairment, with overall exposure much higher (AUC ~1.7-fold mild, ~4.2-fold moderate); severe hepatic impairment was not studied. Renal impairment — parent tapentadol AUC/Cmax were comparable across normal-to-severe renal function, but the inactive tapentadol-O-glucuronide accumulates markedly (up to ~5.5-fold in severe impairment). Half-life figures are from the extended-release label. Not a drug-test detection window and not dosing guidance. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

Can you take tapentadol with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run tapentadol against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is tapentadol sold under?

We track 3 tapentadol-containing products in the U.S.: Nucynta, Nucynta ER and Tapentadol Hydrochloride. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does tapentadol come in?

Across the brands we track, tapentadol is currently marketed as tablet and tablet, extended release, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic tapentadol?

Yes. Our catalog lists 1 generic tapentadol product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

How long does Nucynta (tapentadol) stay in your system?

"In your system" means two different things. First is clearance: tapentadol has a short elimination half-life of about 4 to 5 hours for immediate-release tablets, per the FDA prescribing information. Because a drug is largely eliminated after roughly 4 to 5 half-lives, most of a single immediate-release dose is cleared in about 1 day, with the extended-release form taking somewhat longer because it releases slowly. Second is detectability: a drug test can find tapentadol or its main metabolite (tapentadol-O-glucuronide) for longer than the drug stays active, and how long depends entirely on the test type. These are approximate ranges from laboratory and pharmacology references, not guarantees, and only a clinician or testing lab can interpret a specific result.

How long is Nucynta (tapentadol) detectable in a urine drug test?

Urine is the most common test, and tapentadol is typically detectable for about 1 to 3 days after the last dose. A crucial and honest point: tapentadol is an atypical opioid that is structurally different from morphine, so it does not reliably trigger a standard "opiate" immunoassay and is not included on typical 5-panel or 10-panel screens. Detecting it usually requires a test that specifically targets tapentadol, such as LC-MS/MS confirmation, because the drug is largely metabolized and excreted as tapentadol-O-glucuronide rather than as a morphine-like compound. The exact window varies with dose, duration and frequency of use, metabolism, kidney and liver function, hydration, and the specific assay and its cutoff. These are approximate ranges; only the testing lab can interpret an actual result.

How long does Nucynta (tapentadol) show up in blood, saliva, or hair?

Detection windows differ by specimen. Blood and saliva have the shortest windows, generally up to about 1 to 2 days each, which fits tapentadol's short 4-to-5-hour half-life. Hair testing has the longest look-back: because drug deposited in the growing hair shaft grows out over time (roughly 1 cm per month), a standard hair-strand test can reflect tapentadol use for up to about 90 days. All of these are approximate laboratory ranges that vary with dose, frequency of use, and the assay, and because tapentadol is not part of routine opioid panels, specialized targeted testing is required. This information is factual and educational only; it is not advice about passing or altering a test, and no one should stop a prescribed medication without talking to the prescribing clinician.

Cite this page

APA: pharmaranks. (2026, July 24). Tapentadol: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/tapentadol
MLA: “Tapentadol: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/tapentadol.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for tapentadol on DailyMed (NIH) ↗ — including its boxed warning in full.